 Kevin Deane
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 109 | 2024 | 1002 | 17.510 |
Why?
| | Autoantibodies | 62 | 2024 | 1347 | 7.150 |
Why?
| | Rheumatoid Factor | 36 | 2023 | 157 | 5.480 |
Why?
| | Anti-Citrullinated Protein Antibodies | 22 | 2023 | 90 | 4.380 |
Why?
| | Autoimmunity | 22 | 2023 | 812 | 3.420 |
Why?
| | Peptides, Cyclic | 29 | 2023 | 252 | 3.400 |
Why?
| | Antirheumatic Agents | 11 | 2021 | 255 | 1.950 |
Why?
| | Rheumatic Diseases | 4 | 2022 | 49 | 1.850 |
Why?
| | Sputum | 4 | 2021 | 286 | 1.560 |
Why?
| | Immunoglobulin A | 11 | 2023 | 166 | 1.230 |
Why?
| | Lung Diseases, Interstitial | 8 | 2024 | 495 | 1.220 |
Why?
| | Biomarkers | 27 | 2024 | 3397 | 1.090 |
Why?
| | Humans | 132 | 2024 | 114045 | 1.070 |
Why?
| | Autoantigens | 8 | 2023 | 396 | 1.050 |
Why?
| | Disease Progression | 16 | 2021 | 2371 | 0.930 |
Why?
| | Bronchial Diseases | 3 | 2013 | 35 | 0.910 |
Why?
| | Early Medical Intervention | 2 | 2014 | 52 | 0.900 |
Why?
| | Genetic Predisposition to Disease | 16 | 2023 | 2090 | 0.900 |
Why?
| | Extracellular Traps | 3 | 2021 | 40 | 0.880 |
Why?
| | Lung Diseases | 4 | 2022 | 690 | 0.820 |
Why?
| | Rheumatology | 6 | 2021 | 88 | 0.800 |
Why?
| | Inflammation | 9 | 2023 | 2464 | 0.790 |
Why?
| | Early Diagnosis | 8 | 2022 | 217 | 0.790 |
Why?
| | Mosquito Vectors | 1 | 2022 | 21 | 0.780 |
Why?
| | Precision Medicine | 3 | 2020 | 335 | 0.770 |
Why?
| | Insecticides | 1 | 2022 | 31 | 0.770 |
Why?
| | Lupus Erythematosus, Systemic | 4 | 2022 | 220 | 0.770 |
Why?
| | Joints | 4 | 2015 | 83 | 0.760 |
Why?
| | Malaria | 1 | 2022 | 48 | 0.750 |
Why?
| | Arthralgia | 2 | 2021 | 46 | 0.740 |
Why?
| | Middle Aged | 62 | 2022 | 26605 | 0.740 |
Why?
| | Risk Factors | 29 | 2022 | 8614 | 0.740 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 11 | 0.730 |
Why?
| | Epitopes | 8 | 2023 | 434 | 0.700 |
Why?
| | Histones | 4 | 2023 | 529 | 0.670 |
Why?
| | Female | 78 | 2023 | 59324 | 0.670 |
Why?
| | Lung | 7 | 2020 | 3521 | 0.670 |
Why?
| | Male | 67 | 2022 | 55396 | 0.650 |
Why?
| | Citrullination | 2 | 2020 | 12 | 0.650 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 787 | 0.640 |
Why?
| | HIV Infections | 3 | 2021 | 2453 | 0.610 |
Why?
| | Methotrexate | 3 | 2021 | 227 | 0.590 |
Why?
| | Mucous Membrane | 1 | 2018 | 108 | 0.590 |
Why?
| | Immunoglobulin G | 11 | 2023 | 766 | 0.580 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 75 | 0.580 |
Why?
| | Adult | 48 | 2022 | 30375 | 0.570 |
Why?
| | Pedigree | 2 | 2020 | 460 | 0.560 |
Why?
| | Synovitis | 2 | 2023 | 24 | 0.540 |
Why?
| | Citrulline | 2 | 2016 | 39 | 0.540 |
Why?
| | Case-Control Studies | 15 | 2023 | 3003 | 0.530 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 53 | 0.530 |
Why?
| | Human Migration | 1 | 2016 | 19 | 0.520 |
Why?
| | Transients and Migrants | 1 | 2016 | 22 | 0.520 |
Why?
| | Autoimmune Diseases | 4 | 2023 | 381 | 0.520 |
Why?
| | Arthritis | 2 | 2016 | 109 | 0.500 |
Why?
| | Aged | 34 | 2022 | 18969 | 0.500 |
Why?
| | Immunoglobulin M | 7 | 2023 | 245 | 0.490 |
Why?
| | Cytokines | 10 | 2023 | 1824 | 0.470 |
Why?
| | Family | 7 | 2021 | 589 | 0.470 |
Why?
| | Pneumonia | 1 | 2020 | 563 | 0.470 |
Why?
| | Prospective Studies | 19 | 2022 | 6195 | 0.460 |
Why?
| | Sexual Behavior | 2 | 2016 | 434 | 0.460 |
Why?
| | Endothelium, Vascular | 4 | 2013 | 830 | 0.430 |
Why?
| | Risk-Taking | 1 | 2016 | 333 | 0.430 |
Why?
| | Chemokines | 2 | 2012 | 215 | 0.420 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2013 | 43 | 0.420 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 200 | 0.410 |
Why?
| | Tanzania | 3 | 2021 | 42 | 0.410 |
Why?
| | Hazardous Substances | 1 | 2012 | 9 | 0.400 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 90 | 0.400 |
Why?
| | Mass Screening | 3 | 2020 | 979 | 0.400 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.370 |
Why?
| | Smoking | 9 | 2024 | 1382 | 0.370 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 122 | 0.370 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 182 | 0.360 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 399 | 0.360 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.360 |
Why?
| | Research Design | 3 | 2024 | 919 | 0.350 |
Why?
| | Emigration and Immigration | 1 | 2010 | 45 | 0.350 |
Why?
| | Acetaldehyde | 2 | 2020 | 15 | 0.350 |
Why?
| | Malondialdehyde | 2 | 2020 | 28 | 0.340 |
Why?
| | Postmenopause | 7 | 2023 | 301 | 0.340 |
Why?
| | Health Fairs | 1 | 2009 | 9 | 0.340 |
Why?
| | Antibodies, Antinuclear | 5 | 2023 | 58 | 0.340 |
Why?
| | Glucocorticoids | 3 | 2021 | 526 | 0.320 |
Why?
| | Incidence | 9 | 2021 | 2314 | 0.310 |
Why?
| | Antibodies, Bacterial | 3 | 2023 | 119 | 0.310 |
Why?
| | Mucin-5B | 2 | 2022 | 184 | 0.300 |
Why?
| | Synovial Membrane | 3 | 2023 | 74 | 0.300 |
Why?
| | Health Behavior | 3 | 2018 | 701 | 0.280 |
Why?
| | Cross-Sectional Studies | 9 | 2023 | 4402 | 0.280 |
Why?
| | Antibody Formation | 4 | 2023 | 266 | 0.260 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 21 | 0.250 |
Why?
| | Vasculitis | 1 | 2005 | 65 | 0.250 |
Why?
| | Risk Assessment | 6 | 2020 | 2958 | 0.230 |
Why?
| | Qualitative Research | 2 | 2021 | 919 | 0.230 |
Why?
| | Polysaccharides | 2 | 2017 | 78 | 0.220 |
Why?
| | Risk | 3 | 2016 | 810 | 0.220 |
Why?
| | Estrogens | 3 | 2017 | 312 | 0.220 |
Why?
| | Time Factors | 6 | 2019 | 6077 | 0.220 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.210 |
Why?
| | Periodontal Diseases | 1 | 2023 | 54 | 0.200 |
Why?
| | Mouth Mucosa | 3 | 2023 | 79 | 0.200 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.200 |
Why?
| | Trichloroethylene | 1 | 2022 | 7 | 0.200 |
Why?
| | Biological Products | 2 | 2022 | 166 | 0.200 |
Why?
| | Prevalence | 4 | 2022 | 2247 | 0.200 |
Why?
| | Patient Education as Topic | 2 | 2018 | 666 | 0.200 |
Why?
| | Insecticide-Treated Bednets | 1 | 2022 | 3 | 0.200 |
Why?
| | Sex Factors | 5 | 2020 | 1706 | 0.200 |
Why?
| | Women's Health | 5 | 2017 | 270 | 0.190 |
Why?
| | Hemorrhage | 1 | 2005 | 600 | 0.190 |
Why?
| | Organ Specificity | 2 | 2019 | 266 | 0.180 |
Why?
| | Retrospective Studies | 5 | 2024 | 12521 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.180 |
Why?
| | Housing | 1 | 2022 | 114 | 0.180 |
Why?
| | Sarcoidosis | 1 | 2022 | 133 | 0.180 |
Why?
| | Neutrophil Activation | 1 | 2021 | 78 | 0.180 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 84 | 0.180 |
Why?
| | Severity of Illness Index | 8 | 2022 | 2537 | 0.180 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 54 | 0.180 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 |
Why?
| | Social Stigma | 1 | 2021 | 85 | 0.170 |
Why?
| | Animals | 8 | 2022 | 31565 | 0.170 |
Why?
| | Complement System Proteins | 2 | 2022 | 281 | 0.170 |
Why?
| | Museums | 1 | 2000 | 7 | 0.170 |
Why?
| | Intestines | 2 | 2021 | 325 | 0.170 |
Why?
| | Bacteriophages | 1 | 2021 | 75 | 0.170 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 41 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.170 |
Why?
| | Muramidase | 1 | 2020 | 72 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 180 | 0.170 |
Why?
| | Art Therapy | 1 | 2000 | 14 | 0.170 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.170 |
Why?
| | Age Factors | 7 | 2020 | 2885 | 0.170 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 81 | 0.170 |
Why?
| | Attitude | 1 | 2021 | 228 | 0.160 |
Why?
| | Young Adult | 8 | 2021 | 10444 | 0.160 |
Why?
| | Occupational Exposure | 1 | 2022 | 255 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 48 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2020 | 475 | 0.160 |
Why?
| | Dexamethasone | 1 | 2020 | 316 | 0.160 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 30 | 0.150 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 46 | 0.150 |
Why?
| | Gene Expression | 2 | 2022 | 1417 | 0.150 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 130 | 0.150 |
Why?
| | Cohort Studies | 10 | 2022 | 4883 | 0.150 |
Why?
| | Cellular Senescence | 1 | 2019 | 151 | 0.150 |
Why?
| | Vascular Stiffness | 2 | 2013 | 410 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 503 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 489 | 0.150 |
Why?
| | Metabolome | 1 | 2020 | 274 | 0.150 |
Why?
| | Global Health | 1 | 2020 | 284 | 0.150 |
Why?
| | United States | 8 | 2022 | 12137 | 0.140 |
Why?
| | HLA-DR4 Antigen | 3 | 2007 | 76 | 0.140 |
Why?
| | Remission Induction | 2 | 2021 | 233 | 0.140 |
Why?
| | Galactose | 1 | 2017 | 20 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1128 | 0.140 |
Why?
| | Military Personnel | 2 | 2021 | 521 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 926 | 0.140 |
Why?
| | Adiponectin | 1 | 2018 | 213 | 0.140 |
Why?
| | Glycosylation | 1 | 2017 | 130 | 0.140 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 500 | 0.140 |
Why?
| | Coronary Disease | 2 | 2017 | 348 | 0.140 |
Why?
| | Estradiol | 3 | 2017 | 450 | 0.130 |
Why?
| | Seroepidemiologic Studies | 3 | 2014 | 137 | 0.130 |
Why?
| | Plasma Cells | 1 | 2016 | 56 | 0.130 |
Why?
| | Sex Work | 1 | 2016 | 18 | 0.130 |
Why?
| | Hydrolases | 2 | 2021 | 51 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1690 | 0.130 |
Why?
| | Neutrophils | 1 | 2021 | 1089 | 0.130 |
Why?
| | HLA Antigens | 1 | 2017 | 220 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1331 | 0.130 |
Why?
| | Peptides | 1 | 2021 | 847 | 0.130 |
Why?
| | Diet | 2 | 2020 | 1080 | 0.130 |
Why?
| | Mitochondria | 1 | 2021 | 744 | 0.130 |
Why?
| | Cardiovascular Diseases | 3 | 2017 | 1726 | 0.130 |
Why?
| | Adaptation, Psychological | 1 | 2000 | 545 | 0.120 |
Why?
| | Vasodilation | 3 | 2013 | 418 | 0.120 |
Why?
| | Neoplasms | 2 | 2017 | 2086 | 0.120 |
Why?
| | Alcohol Drinking | 1 | 2020 | 650 | 0.120 |
Why?
| | Tertiary Prevention | 1 | 2014 | 3 | 0.120 |
Why?
| | Focus Groups | 1 | 2016 | 378 | 0.120 |
Why?
| | C-Reactive Protein | 5 | 2018 | 362 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 949 | 0.110 |
Why?
| | Blood Pressure | 2 | 2017 | 1531 | 0.110 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 251 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 828 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2014 | 221 | 0.110 |
Why?
| | Bacteroidaceae Infections | 1 | 2012 | 4 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.100 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 140 | 0.100 |
Why?
| | Porphyromonas gingivalis | 1 | 2012 | 17 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 172 | 0.100 |
Why?
| | Vitamin D | 2 | 2022 | 340 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2014 | 321 | 0.100 |
Why?
| | Family Health | 2 | 2013 | 193 | 0.100 |
Why?
| | Population Surveillance | 1 | 2015 | 385 | 0.100 |
Why?
| | Periodontitis | 1 | 2012 | 41 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2023 | 1846 | 0.100 |
Why?
| | Health | 1 | 2012 | 74 | 0.100 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.100 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 1791 | 0.100 |
Why?
| | Telomere Shortening | 2 | 2024 | 17 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 103 | 0.100 |
Why?
| | Delayed Diagnosis | 1 | 2012 | 71 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1078 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4392 | 0.090 |
Why?
| | Phenotype | 4 | 2023 | 2784 | 0.090 |
Why?
| | Disease Susceptibility | 3 | 2021 | 316 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2020 | 2764 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 146 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2384 | 0.090 |
Why?
| | Logistic Models | 5 | 2020 | 1829 | 0.090 |
Why?
| | Labor, Induced | 1 | 2011 | 32 | 0.090 |
Why?
| | Air Pollution | 1 | 2013 | 169 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1168 | 0.090 |
Why?
| | Cyclophosphamide | 1 | 2011 | 214 | 0.090 |
Why?
| | Rituximab | 1 | 2011 | 148 | 0.090 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 122 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 2012 | 302 | 0.080 |
Why?
| | Colorado | 3 | 2020 | 4090 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2021 | 9049 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 384 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 271 | 0.080 |
Why?
| | Aging | 1 | 2019 | 1611 | 0.080 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 286 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 89 | 0.080 |
Why?
| | Interleukin-6 | 3 | 2021 | 673 | 0.080 |
Why?
| | Obesity | 1 | 2020 | 2505 | 0.080 |
Why?
| | Aspirin | 1 | 2011 | 324 | 0.080 |
Why?
| | Odds Ratio | 3 | 2018 | 951 | 0.080 |
Why?
| | Alleles | 3 | 2019 | 789 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2010 | 305 | 0.070 |
Why?
| | Societies, Medical | 2 | 2021 | 655 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 493 | 0.070 |
Why?
| | Brachial Artery | 3 | 2013 | 176 | 0.070 |
Why?
| | Stroke | 1 | 2015 | 1019 | 0.070 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 23 | 0.070 |
Why?
| | Capillaries | 1 | 2005 | 90 | 0.060 |
Why?
| | Environment | 2 | 2019 | 333 | 0.060 |
Why?
| | Premenopause | 2 | 2017 | 105 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 150 | 0.060 |
Why?
| | Bronchoscopy | 1 | 2005 | 196 | 0.060 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 42 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2017 | 191 | 0.060 |
Why?
| | Immunity, Mucosal | 2 | 2014 | 84 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2016 | 413 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2023 | 29 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 372 | 0.050 |
Why?
| | Vimentin | 1 | 2023 | 58 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 365 | 0.050 |
Why?
| | Body Mass Index | 2 | 2020 | 1957 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 4595 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 1024 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1422 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 202 | 0.050 |
Why?
| | Immunoglobulins | 2 | 2015 | 143 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2022 | 285 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 641 | 0.050 |
Why?
| | Mice | 3 | 2022 | 14843 | 0.050 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 10 | 0.050 |
Why?
| | Carotid Arteries | 2 | 2013 | 180 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 124 | 0.050 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 39 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2012 | 2272 | 0.050 |
Why?
| | Xenobiotics | 1 | 2021 | 24 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 150 | 0.050 |
Why?
| | Putrescine | 1 | 2020 | 2 | 0.050 |
Why?
| | Butyric Acid | 1 | 2020 | 5 | 0.050 |
Why?
| | Microbiota | 2 | 2021 | 648 | 0.050 |
Why?
| | Genetic Markers | 1 | 2022 | 320 | 0.050 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 69 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2010 | 3498 | 0.050 |
Why?
| | Spermidine | 1 | 2020 | 16 | 0.040 |
Why?
| | Caprylates | 1 | 2020 | 19 | 0.040 |
Why?
| | Europe | 1 | 2021 | 332 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 66 | 0.040 |
Why?
| | Carnitine | 1 | 2020 | 62 | 0.040 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2020 | 7 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1206 | 0.040 |
Why?
| | B-Cell Activating Factor | 1 | 2020 | 18 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 56 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 21 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 229 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 62 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 144 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 34 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 396 | 0.040 |
Why?
| | Ontario | 1 | 2000 | 77 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 274 | 0.040 |
Why?
| | Interleukin-1alpha | 1 | 2020 | 55 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 175 | 0.040 |
Why?
| | Interinstitutional Relations | 1 | 2000 | 54 | 0.040 |
Why?
| | Tryptophan | 1 | 2020 | 136 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 3315 | 0.040 |
Why?
| | Baltimore | 1 | 2019 | 43 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 169 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5499 | 0.040 |
Why?
| | Interferons | 1 | 2020 | 151 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 615 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 211 | 0.040 |
Why?
| | Genotype | 2 | 2018 | 1757 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 532 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 368 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 268 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 762 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 522 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 520 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 145 | 0.040 |
Why?
| | Nurses | 1 | 2020 | 145 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2018 | 16 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 229 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 331 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 236 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 98 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 686 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 381 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 1880 | 0.040 |
Why?
| | Decision Support Techniques | 1 | 2021 | 336 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 476 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 429 | 0.040 |
Why?
| | Phylogeny | 1 | 2021 | 787 | 0.040 |
Why?
| | Amino Acids | 1 | 2021 | 445 | 0.040 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.040 |
Why?
| | Raloxifene Hydrochloride | 1 | 2017 | 13 | 0.040 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 19 | 0.030 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2017 | 26 | 0.030 |
Why?
| | Leuprolide | 1 | 2017 | 19 | 0.030 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2017 | 34 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 6 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 49 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 14 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 725 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 337 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 17800 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 58 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 595 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1257 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1735 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 86 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 694 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2000 | 571 | 0.030 |
Why?
| | Health Education | 1 | 2018 | 317 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 723 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2017 | 189 | 0.030 |
Why?
| | Androgens | 1 | 2017 | 167 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2016 | 119 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6306 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2550 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 292 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 90 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1131 | 0.030 |
Why?
| | Motivation | 1 | 2018 | 488 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 722 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 341 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2014 | 97 | 0.030 |
Why?
| | Etanercept | 1 | 2013 | 51 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 437 | 0.030 |
Why?
| | Communication | 1 | 2018 | 734 | 0.030 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 7 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 37 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1447 | 0.030 |
Why?
| | Interleukin-9 | 1 | 2012 | 10 | 0.030 |
Why?
| | Cell Membrane | 1 | 2016 | 670 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2016 | 459 | 0.030 |
Why?
| | Oral Health | 1 | 2014 | 139 | 0.030 |
Why?
| | Life Style | 1 | 2014 | 428 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 281 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 140 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2014 | 217 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3338 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 568 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 185 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 71 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 1642 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 255 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 990 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 296 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1080 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 473 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2012 | 522 | 0.020 |
Why?
| | Internet | 1 | 2014 | 591 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 590 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 635 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 695 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 719 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2322 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1469 | 0.020 |
Why?
| | Hypertension | 1 | 2015 | 1052 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 898 | 0.020 |
Why?
| | Veterans | 1 | 2018 | 1248 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 20 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 115 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 217 | 0.010 |
Why?
| | Siblings | 1 | 2005 | 220 | 0.010 |
Why?
| | Child | 2 | 2007 | 18401 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 9114 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3254 | 0.010 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|